Alexion Pharmaceuticals’ (ALXN) third-quarter 2014 earnings (including stock-based compensation expense) of $1.14 per share beat the Zacks Consensus Estimate by 9 cents. The earnings beat was attributable to higher-than-expected revenues. Moreover, earnings were above the year-ago figure by 56.2%. Including one-time items, Alexion’s earnings climbed 87% year over year to 88 cents per share in…
Celgene Corporation (CELG) reported third-quarter 2014 earnings of 88 cents per share (including stock-based compensation expenses), which surpassed the Zacks Consensus Estimate by 6 cents. The company’s earnings were $1.39 per share in the year-ago quarter. We note that figures have been adjusted to reflect the two-for-one stock split effected earlier in the year. Total…
Gilead Sciences (GILD) has been a leader in the resurgent Biotech group. Gilead recovered from the steep drop in the Biotech group in March and April and has been outperforming the group and the overall market since mid-May. With GILD leading the Biotech stocks to new highs, all eyes will be on their earnings report…
Harvoni is the new tablet launched this month by Gilead Sciences, Inc (NASDAQ GILD) which Stewart acquired first because she take part in its clinical trials. Harvoni is a mixture of the novel drug ledipasvir and sofosbuvir, which for closely a year has been sold only under the brand name Sovaldi. Sovaldi’s launch shattered all…
Biotechnology investors often have to make bets based more on promise than profit. That’s because it takes years and hundreds of millions of dollars to advance new medicine through clinical trials to market, so investing in biotech stocks is more of a gamble than investing in other industries. Having said that, there are a number…
Biotech stocks to buy aren’t exactly the most popular investments on Wall Street right now. The “risk on” environment of 2013 seems to have evaporated, with volatility heating up and many investors taking shelter in old stalwarts like consumer staples and even bond funds. Biotech stocks are often seen as risky and more speculative by…
